Preferred Partners
Overview
Canbiotech has entered a strategic partnership with NanoSALV’s developer/manufacturer to bring NanoSALV Gel to the Asia-Pacific region. Under this arrangement, CanBioTech will serve as the preferred distribution partner for NanoSALV, enabling access starting with Hong Kong.
Key Elements of the Partnership
| Feature | Description |
|---|---|
| Distribution Role | CanBioTech acts as a trusted channel to import, register, and distribute NanoSALV Gel in Hong Kong. |
| Preferred Distributor Status | While not exclusive globally, CanBioTech holds preferred access for Hong Kong, meaning all national distributors must interface through CanBioTech to gain access to NanoSALV in the region. |
| Regulatory & Compliance Support | CanBioTech will manage regulatory filings, import licensing, quality assurance, and product registration standards across Hong Kong jurisdictions. |
| Logistics & Supply Chain | CanBioTech will establish warehousing, cold chain or control-storage (if required), and distribution networks to hospitals, clinics, pharmacies, and care centers in all. |
| Market Entry & Launch Strategy | The initial launch will be in Hong Kong to build reputation and local validation; subsequent expansion into Greater Bay Area (Southern China) and Southeast Asian markets is planned. |
| Brand & Commercial Rights | The partnership ensures that NanoSALV’s branding, IP, and clinical data support is visible and consistent across all markets, reinforcing confidence among hospitals and clinicians. |
| Growth & Portfolio Leverage | As NanoSALV gains adoption, the partnership serves as a beachhead. CanBioTech can expand into further product lines (e.g. Bioflex therapies, BioStem biologics, Deep Blue surgical products) under the same distribution framework. |
Strategic Benefits
First-Mover Advantage in APAC: NanoSALV will benefit from being introduced through a local distribution channel with market knowledge and regulatory experience.
Channel Control Without Full Exclusivity: By holding preferred distributor status, CanBioTech ensures that all downstream distribution in APAC flows through its infrastructure, giving it influence without needing global exclusivity.
Risk Mitigation: CanBioTech’s capabilities in regulatory, logistics, and medical sales reduce the operational risk for the manufacturer, making APAC expansion more attractive.
Scalability: The infrastructure built for NanoSALV can be reused for other North American medical technologies, enabling a broader product portfolio with lower incremental cost.
Credibility & Trust: Local presence, clinical validation, and consistent supply chain management increase trust from hospitals, governments, and clinicians in the APAC region.
Vision & Outlook
Together, CanBioTech and NanoSALV aim to transform access to advanced wound care in Asia-Pacific. NanoSALV Gel will be the flagship product, demonstrating effectiveness and building momentum, after which a broader portfolio of cutting-edge North American medical technologies will be introduced under this partnership. The long-term vision is to make CanBioTech HK the go-to gateway for APAC access to North American wound care innovations.
BioFlex is a leading laser therapy system developed in Canada with over 35 years of clinical use. It uses low-intensity red and infrared light to stimulate healing, reduce pain, and control inflammation.
-
Safe & Non-Invasive: FDA and Health Canada approved, with no significant side effects.
-
Proven Track Record: More than 3.5 million treatments delivered worldwide.
-
Wound Care Applications: Helps accelerate healing of chronic wounds, ulcers, and surgical injuries.
At Canbiotech, BioFlex serves as a peripheral product in our portfolio — complementing our flagship NanoSALV Gel and future biologic and surgical solutions. It strengthens our mission of bringing North America’s best medical technologies to Asia-Pacific.